Sinocelltech Group Ltd (SHA: 688520), based in China, has announced that it has received clearance from the National Medical Products Administration (NMPA) to initiate a clinical study for its investigational bispecific antibody (BsAb), SCTB35. This novel molecule targets both CD20 and CD3 and is being evaluated as a treatment for CD20-positive B-cell non-Hodgkin’s lymphoma (nHL).
Notably, Roche’s Columvi (glofitamab), another CD20/CD3 BsAb, was recently approved in China for the treatment of recurrent or refractory diffuse large B-cell lymphoma (DLBCL) in patients who have undergone at least two lines of systemic therapy, receiving its nod in November 2023.- Flcube.com
